Literature DB >> 2423869

Effector mechanisms in myasthenia gravis: end-plate function after passive transfer of IgG, Fab, and F(ab')2 hybrid molecules.

R Sterz, R Hohlfeld, K Rajki, M Kaul, K Heininger, K Peper, K V Toyka.   

Abstract

Using the quantitative ionophoresis technique and the mouse passive transfer model of myasthenia gravis, end-plate function was measured in mice transferred with myasthenic IgG, Fab, or F(ab')2 hybrid molecules prepared by recombination of one acetylcholine receptor (AChR) specific Fab and one Fab directed against irrelevant antigen. The Hill coefficient (a measure for the cooperativity between AChR subunits) and the apparent dissociation constant K for the ACh-AChR interaction were essentially unaltered after passive transfer of IgG or IgG fragments. In contrast, myasthenic IgG and Fab, but not control IgG or Fab, markedly reduced the mean number of end-plate channels. A similar effect was observed after passive transfer of F(ab')2 hybrid molecules. These results show that passive transfer of myasthenic IgG or IgG fragments leads to a quantitative reduction of ACh-controlled end-plate channels, whereas the function of the remaining receptors/channels remains unchanged. The results suggest further that cross-linking of AChR by divalent antibody may not be an absolute requirement for the reduction of AChR at the functional neuromuscular synapse.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423869     DOI: 10.1002/mus.880090404

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  13 in total

1.  Treatment of passively transferred experimental autoimmune myasthenia gravis using papain.

Authors:  K Poulas; T Tsouloufis; S J Tzartos
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.

Authors:  Jason A Vander Heiden; Panos Stathopoulos; Julian Q Zhou; Luan Chen; Tamara J Gilbert; Christopher R Bolen; Richard J Barohn; Mazen M Dimachkie; Emma Ciafaloni; Teresa J Broering; Francois Vigneault; Richard J Nowak; Steven H Kleinstein; Kevin C O'Connor
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

Review 3.  Immunopathogenesis and treatment of myasthenia gravis.

Authors:  A I Levinson; B Zweiman; R P Lisak
Journal:  J Clin Immunol       Date:  1987-05       Impact factor: 8.317

Review 4.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

5.  Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs.

Authors:  Linda L Kusner; Mario Losen; Angela Vincent; Jon Lindstrom; Socrates Tzartos; Konstantinos Lazaridis; Pilar Martinez-Martinez
Journal:  Exp Neurol       Date:  2015-03-03       Impact factor: 5.330

Review 6.  Novel pathophysiological insights in autoimmune myasthenia gravis.

Authors:  Gianvito Masi; Kevin C O'Connor
Journal:  Curr Opin Neurol       Date:  2022-08-04       Impact factor: 6.283

7.  Elevated N-Linked Glycosylation of IgG V Regions in Myasthenia Gravis Disease Subtypes.

Authors:  Caleigh Mandel-Brehm; Miriam L Fichtner; Ruoyi Jiang; Valerie J Winton; Sara E Vazquez; Minh C Pham; Kenneth B Hoehn; Neil L Kelleher; Richard J Nowak; Steven H Kleinstein; Michael R Wilson; Joseph L DeRisi; Kevin C O'Connor
Journal:  J Immunol       Date:  2021-09-20       Impact factor: 5.426

8.  Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis.

Authors:  Ruoyi Jiang; Kenneth B Hoehn; Casey S Lee; Minh C Pham; Robert J Homer; Frank C Detterbeck; Inmaculada Aban; Leslie Jacobson; Angela Vincent; Richard J Nowak; Henry J Kaminski; Steven H Kleinstein; Kevin C O'Connor
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-16       Impact factor: 11.205

9.  Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor.

Authors:  J Bufler; S Kahlert; S Tzartos; K V Toyka; A Maelicke; C Franke
Journal:  J Physiol       Date:  1996-04-01       Impact factor: 5.182

10.  Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-γ, and GM-CSF and Diminished IL-10 Production.

Authors:  Yonghao Cao; Robert A Amezquita; Steven H Kleinstein; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  J Immunol       Date:  2016-01-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.